{"id":7,"date":"2025-03-26T10:00:00","date_gmt":"2025-03-26T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=7"},"modified":"2025-09-01T13:52:40","modified_gmt":"2025-09-01T13:52:40","slug":"china-approved-innovation-drugs-in-year-2024","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/7.html","title":{"rendered":"[China BD 2025] Hengrui and MSD enters a 2 billion USD license for oral Lpa inhibitor HRS-5346"},"content":{"rendered":"\n<p><\/p>\n\n\n\n<p>Announced Date: 2025-03-25 (March 25, 2025)<\/p>\n\n\n\n<p>Asset Name: HRS-5346<\/p>\n\n\n\n<p>Licensor: Hengrui Pharma (Jiangsu Hengrui Pharmaceuticals Co., China)<\/p>\n\n\n\n<p>Licensee (Buyer): MSD \uff08Merck &amp; Co., Inc\uff0cUSA\uff09<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small Molecule, oral<\/p>\n\n\n\n<p>Asset Target: Lipoprotein(a) inhibitor\u00a0, or Lp(a) inhibitor\u00a0<\/p>\n\n\n\n<p>Current Stage: Phase II, China<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Hengrui Pharma has granted MSD exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region(China Mainland, Hong Kong, Macau and Taiwan) <\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of\u00a0$200 million,<\/p>\n\n\n\n<p>Milestone payments up to \u00a0approximately $1.77 billion.<\/p>\n\n\n\n<p>Total 1.97 billion plus<\/p>\n\n\n\n<p>Royalties on net sales, \u00a0tiered<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p>MSD Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.msd.com\/news\/msd-enters-exclusive-license-agreement-for-hrs-5346-an-investigational-oral-lipoproteina-inhibitor-for-cardiovascular-disease-from-jiangsu-hengrui-pharmaceuticals-co-ltd\/\" data-type=\"link\" data-id=\"https:\/\/www.msd.com\/news\/msd-enters-exclusive-license-agreement-for-hrs-5346-an-investigational-oral-lipoproteina-inhibitor-for-cardiovascular-disease-from-jiangsu-hengrui-pharmaceuticals-co-ltd\/\">https:\/\/www.msd.com\/news\/msd-enters-exclusive-license-agreement-for-hrs-5346-an-investigational-oral-lipoproteina-inhibitor-for-cardiovascular-disease-from-jiangsu-hengrui-pharmaceuticals-co-ltd\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-03-25 (March 25, 2025) Asset Name: HRS-5346 Licensor: Hengrui Pharma (Jiangsu Hengrui Pharmaceuticals Co., &hellip; <a title=\"[China BD 2025] Hengrui and MSD enters a 2 billion USD license for oral Lpa inhibitor HRS-5346\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/7.html\"><span class=\"screen-reader-text\">[China BD 2025] Hengrui and MSD enters a 2 billion USD license for oral Lpa inhibitor HRS-5346<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/7","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=7"}],"version-history":[{"count":4,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/7\/revisions"}],"predecessor-version":[{"id":130,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/7\/revisions\/130"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=7"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=7"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=7"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}